Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Rhea-AI Summary
Biofrontera (Nasdaq: BFRI) reported preliminary, unaudited fourth quarter 2025 revenue between $17.0 million and $17.5 million, the highest quarterly revenue in company history and reflecting approximately 35% to 39% year-over-year growth. Full year 2025 revenues are expected to be $41.5 million to $42.0 million, or roughly 11% to 13% growth versus 2024. Management attributed Q4 performance to strong Ameluz® sales and a December pricing adjustment, and noted a transactional change with Biofrontera AG that management says improves gross margin profile. Results remain preliminary and unaudited; final fourth quarter and full year 2025 financials will be reported in March 2026.
Positive
- Q4 revenue $17.0–$17.5M, highest quarterly revenue
- Q4 growth ~35%–39% year-over-year
- Full-year 2025 revenue $41.5–$42.0M (+11%–13%)
- Ameluz sales drove strong quarter performance
- Transaction with Biofrontera AG improves gross margin profile
Negative
- Preliminary unaudited figures subject to change
- Q4 growth reported as a range (35%–39%), reflecting uncertainty
- Final 2025 results not expected until March 2026
News Market Reaction
On the day this news was published, BFRI gained 0.93%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.7% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $85K to the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, BFRI was down 3.51% while peers were mixed: EVOK up 0.18%, YCBD up 11.54%, and IMCC, SBFM, SNOA down between 0.71% and 4.72%, suggesting stock-specific dynamics rather than a sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Clinical trial update | Positive | +3.1% | Phase 3 AK and Phase 2 acne databases locked enabling topline data. |
| Dec 18 | Regulatory transfer | Positive | +5.6% | Completed transfer of Ameluz and RhodoLED FDA approvals and IP portfolio. |
| Dec 04 | Clinical trial update | Positive | +3.2% | Last patient completed Phase 1 PK study for Ameluz on trunk and extremities. |
| Dec 02 | Regulatory filing | Positive | -0.1% | Filed sNDA for Ameluz-PDT to treat superficial basal cell carcinoma. |
| Nov 13 | Earnings update | Negative | -8.6% | Q3 2025 revenue decline and going-concern disclosure alongside U.S. rights deal. |
Recent news reactions mostly aligned with the tone of the announcements, with only one mild divergence on a positive regulatory update.
Over the last few months, Biofrontera reported several positive clinical and regulatory milestones tied to Ameluz® PDT. Database locks for Phase 3 AK and Phase 2 acne studies on Jan 5, 2026 and completion of a Phase 1 PK study in Nov 2025 supported expansion plans. The company also submitted an sBCC sNDA based on strong Phase 3 data and completed transfer of Ameluz and RhodoLED FDA approvals, gaining full US control. November earnings highlighted revenue pressure and going‑concern risks. Today’s record preliminary Q4 2025 revenues build on this transition toward full ownership and commercialization scale.
Market Pulse Summary
This announcement highlights record preliminary Q4 2025 revenues of $17.0–$17.5 million and full‑year 2025 growth of 11%–13%, driven by Ameluz® PDT and pricing changes. Set against recent clinical and regulatory milestones, it underscores progress in scaling U.S. commercialization after acquiring full Ameluz and RhodoLED rights. Investors may watch final audited results in March 2026, cash and profitability trends, and upcoming clinical readouts to gauge the durability of this revenue inflection.
Key Terms
photodynamic therapy medical
pdt medical
AI-generated analysis. Not financial advice.
- Fourth quarter results represent highest quarterly revenue in Company’s history
- Q4 year-over-year growth of
35% to39% driven by sales execution of Ameluz® - Full year 2025 revenues also expected to show double-digit growth of
11% to13%
WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between
For the full year 2025, revenues are expected to be in the range of
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, commented “We are very pleased with our fourth quarter performance which was driven by strong execution across the business, continued growth of Ameluz® PDT and the pricing adjustment introduced in December. Customer adoption and engagement remained strong throughout the quarter, supporting record quarterly revenue performance, validating our strategic approach and setting us up for even stronger momentum throughout 2026.
Just as exciting, our recent transformational transaction with Biofrontera AG meaningfully improves our gross margin profile and further strengthens our financial foundation. We’ve never been more energized about the year ahead, and we’re confident that our innovative products, operational excellence, and unwavering commitment to customers will drive continued, sustainable growth.”
Results for the quarter and year ended December 31, 2025, have not been finalized and are subject to our financial statement closing procedures. As such, the preliminary unaudited figures described in this press release are subject to change, and actual results may differ. Biofrontera expects to report final, complete fourth quarter and full year financial results for 2025 in March 2026. Details concerning that announcement and conference call will be provided in the coming weeks.
Biofrontera management will present at the Lytham Partners Healthcare Investor Summit on January 15, 2026.
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
1 https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's preliminary financial results, revenue growth, commercial opportunities and the commercial success of its products, and other statements that are not historical facts. The words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “target”, “goal”, “assume”, “would”, “could” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz ® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s products; whether the market opportunity for Ameluz ® in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations
Lytham Partners
Ben Shamsian
shamsian@lythampartners.com
646-829-9701
FAQ
What were Biofrontera (BFRI) preliminary Q4 2025 revenues?
How much did Biofrontera (BFRI) revenue grow in Q4 2025 year-over-year?
What is Biofrontera's (BFRI) expected full-year 2025 revenue?
Why did Biofrontera (BFRI) say Q4 2025 was strong?
Has Biofrontera (BFRI) finalized its 2025 results?
What did Biofrontera (BFRI) say about the Biofrontera AG transaction?
